The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pathologic correlation of 18F-16β-fluoro-5α-dihydrotestosterone (FDHT) and FDG PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Jarett L. Feldman
No relevant relationships to disclose
Josef J. Fox
No relevant relationships to disclose
Danny F. Martinez
No relevant relationships to disclose
Karen A. Autio
No relevant relationships to disclose
Jeremy C. Durack
No relevant relationships to disclose
John Humm
No relevant relationships to disclose
Heiko Schöder
No relevant relationships to disclose
Somali C. Gavane
No relevant relationships to disclose
Kristen Rebecca Curtis
No relevant relationships to disclose
Samantha Meredith Balakirsky
No relevant relationships to disclose
Rachel Mathilda Cohen
No relevant relationships to disclose
Howard I. Scher
Consultant or Advisory Role - Bristol-Myers Squibb (U); Celgene (U); Exelixis (U); Janssen Diagnostics (U); Janssen Pharmaceutical (U); Medivation (U); Millennium; Orion-Endo Pharmaceuticals
Research Funding - Janssen Diagnostics; Janssen Pharmaceutical ; Medivation
Steven M. Larson
No relevant relationships to disclose
Michael J. Morris
Consultant or Advisory Role - Bayer (U); Janssen (U); Millennium
Research Funding - Bayer; Sanofi